×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Kidney Cancer
Katie Kosko
Many patients with renal cell carcinoma, the most common type of kidney cancer, experience high levels of distress, according to study findings published in BJU International.
DEBORAH ABRAMS KAPLAN
Targeted drugs are controversial in early-stage kidney cancer, but play a more important role in treating advanced disease.
Katie Kosko
More than 20 percent of patients with non–clear cell renal cell carcinoma (RCC) had a germline mutation, of which half had the potential to direct systemic therapy.
Katie Kosko
Experts at Roswell Park Comprehensive Cancer Center discovered a way to assess if a kidney tumor is benign or malignant, potentially sparing many from having to undergo surgery.
Kristie L. Kahl
The National Comprehensive Cancer Network updated its Clinical Practice Guidelines to add two new options for the frontline treatment of patients with kidney cancer.
Jason Harris
Immunotherapy pioneers James P. Allison, Ph.D., and Tasuku Honjo, M.D., Ph.D., have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.
Sandy Liu, MD, reviews the current challenges and recent advances in the treatment of renal cell carcinoma, or kidney cancer, as well as what she looks most forward to in the coming years.
Sandy Liu, MD, offers practical advice for patients undergoing treatment for renal cell carcinoma, or kidney cancer, regarding self-education, self-advocacy and adherence to therapy.
Sandy Liu, MD, outlines the available second-line therapeutic options for renal cell carcinoma, or kidney cancer, as well as what factors she considers when selecting from agents in this setting.
Sandy Liu, MD, reflects on the value of targeted agents in the first-line treatment setting of renal cell carcinoma, or kidney cancer, given clinical and personal experience.